Plasma levels of presepsin (Soluble CD14-subtype) as a novel prognostic marker for hemophagocytic syndrome in hematological malignancies

Satoru Nanno, Hideo Koh, Takako Katayama, Masamichi Hashiba, Ayumi Sato, Yosuke Makuuchi, Joji Nagasaki, Masatomo Kuno, Takuro Yoshimura, Hiroshi Okamura, Mitsutaka Nishimoto, Asao Hirose, Mika Nakamae, Takahiko Nakane, Masayuki Hino, Hirohisa Nakamae

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Objective Recent studies suggest that presepsin (soluble CD14-subtype) is a useful diagnostic and prognostic marker for sepsis, with secretion by activated macrophages potentially dependent on phagocytosis of microorganisms. As“hemophagocytosis”is one of the major characteristics in patients with hemophagocytic syndrome (HPS), we hypothesized that presepsin may reflect the phagocytic activity and be a useful prognostic marker for HPS. Therefore, we aimed to assess the prognostic potential of presepsin in secondary HPS in adult patients with hematological malignancies. Methods Between April 2006 and August 2014, we retrospectively examined consecutive patients with HPS whose blood samples were available at our institution and compared the prognostic value of the following in HPS, singly and in combination: plasma presepsin, serum soluble interleukin (IL)-2 receptor (sIL-2R), ferritin, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IL-6 and IL-10. Results A total of 14 patients were enrolled. The median age of the patients was 46.5 years (range, 22-65). In univariable Cox models, there were no significant variables associated with the prognosis. However, in 12 evaluable patients, only the combination of higher median values of presepsin (>1,935 pg/mL) and sIL-2R (>4,585 U/mL) at the onset of HPS was significantly associated with the 90-day mortality (hazard ratio 14.5; 95% CI, 1.47-143.36; p=0.02). Conclusion These results suggest that a composite model of plasma presepsin and serum sIL-2R levels at the onset of HPS might be a novel predictor of the prognosis of patients with hematological malignancies and secondary HPS.

Original languageEnglish
Pages (from-to)2173-2184
Number of pages12
JournalInternal Medicine
Issue number16
Publication statusPublished - 2016
Externally publishedYes


  • Hemophagocytic syndrome
  • Presepsin (soluble CD14-subtype)
  • Prognostic factor
  • Soluble interleukin-2 receptor

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Plasma levels of presepsin (Soluble CD14-subtype) as a novel prognostic marker for hemophagocytic syndrome in hematological malignancies'. Together they form a unique fingerprint.

Cite this